Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
- Registration Number
- NCT01138969
- Lead Sponsor
- Kaohsiung Veterans General Hospital.
- Brief Summary
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Detailed Description
The aim of the prospective, randomized study is to investigate the efficacy of PPI in prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be compared.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 165
- We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months.
- 1.serious disease 2.refuse informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Esomeprazole plus clopidogrel group esomeprazole esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
- Primary Outcome Measures
Name Time Method Recurrent Peptic Ulcer 6 months Number of participants with recurrent peptic ulcer within 6 months
- Secondary Outcome Measures
Name Time Method Peptic Ulcer Bleeding 6 months participants with peptic ulcer bleeding within 6 months
Trial Locations
- Locations (1)
Kaohsiung Veterans General Hospital
🇨🇳Kaohsiung, Taiwan